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Summary.-The serum concentrations of the radiosensitizer metronidazole have
been determined in mice for both oral and intraperitoneal doses of the drug and
these have been related to radiosensitization studies in murine tumour systems.
In preliminary work before a possible clinical trial the serum metronidazole
concentration/time curves have been determined in 7 patients using single doses
of metronidazole of up to 15 g. The data suggest that a linear relationship exists
between the metronidazole dose expressed in mg/kg and the peak serum con-
centration.
The possibility of achieving radiosensitization of tumours in patients after
tolerable doses of metronidazole is discussed in relation to enhancement ratios
determined for in vitro and in vivto systems. It is concluded that predictions from
in vitro systems give values that are probably too optimistic.
SEVERAL methods have been proposed
to reduce the problem caused by hypoxic,
radioresistant tumour cells in the eradica-
tion of solid human tumours by radio-
therapy (Duncan, 1973). One method is
to sensitize selectively the hypoxic cells
using drugs (Emmerson and Howard-
Flanders, 1965). Many drugs have been
identified which sensitize only hypoxic
cells to the lethal effects of radiation and
this property has been associated with
high electron affinity in these compounds
(Adams, 1973). The discovery that met-
ronidazole (Flagyl, May and Baker Ltd)
selectively sensitized anoxic bacteria and
bean roots (Foster and Willson, 1973),
mammalian cells in vitro (Asquith, Foster
and WVillson, 1973; Chapman, Reuvers
and Borsa, 1973; Asquith et al., 1974) and
has a favourable pharmacology and toxic-
ology in man, led to experiments to test
the radiosensitizing efficiency of this drug
in animal tumours and normal tissues in
experimental animals.
No radiosensitization of normal skin
in oxygen breathing mice was noted
using metronidazole doses of up to 3 g/kg
(Denekamp, Michael and Harris, 1974).
Metronidazole has been shown to reduce
the dose needed to cure 50%o of C3H
mice carrying first generation mammary
tumour transplants from 4040 rad for
oxygen breathing controls to 3100 rad
for oxygen breathing metronidazole treat-
ed mice (ER§ 1.3 ± 0.16). A dose of
3400 rad increases the cure rate from
20% in control mice to 700% in the
drug treated mice (Begg, Sheldon and
Foster, 1974).
Metronidazole has also been shown
to enhance radiation induced damage to
a fast growing anaplastic sarcoma and
first generation transplants of C3H mam-
mary tumour when "time to regrow"
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and " cell loss " are used as tests of
damage (Begg et al., 1974). The dosage
of metronidazole used to produce these
tumour radiosensitizing effects in mice
was high (1000-2500 mg/kg body weight).
However, experiments with the trans-
planted KHT sarcoma, using the lung
colony assay technique to assess tumour
cell survival, showed that a significant
enhancement of radiation damage could
be obtained using 250 mg/kg body weight
(Rauth and Kaufman, 1974). A signifi-
cant reduction in the TCD50 of a C3H
mouse mammary carcinoma using only
100 mg/kg has also been demonstrated
(Stone and W;ithers, 1974). This result
is consistent with the in vitro results
which showed that the size of the sensi-
tizing effect of metronidazole changes
only slowly with drug concentration over
a wide range.
In order to estimate the dosage of
metronidazole required to sensitize tu-
nmours in patients, it was necessary to
determine the metronidazole serum con-
centrations necessary to produce detect-
able sensitization in mice and then deter-
mine the oral dosage required to produce
this serum level in man. An estimation
of the dosage required was first made by
extrapolating from data already obtained
for lower doses (McFadzean, 1969; Davies,
1967). These preliminary estimates indi-
cated that the dose to patients would be
high (10 g) and outside the range of
previous clinical experience. However,
" overdoses " of up to 12 g, taken in a
single dose with suicidal intent, of metro-
nidazole were reported to have been well
tolerated (Lewis and Kenna, 1965). The
serum concentrations of metronidazole
after dosages of 4-15 g to 7 cancer patients
receiving radiotherapy, together with the
tolerance to repeated high doses, have
been studied and arereportedin this paper.
MATERIALS AND METHODS
(a) Murine serum concentration of metroni-
dazole.-Four-month old WHT/Ht male
mice in groups of 5 were given doses of
metronidazole from 25 to 2500 mg/kg body
weight either orally or intraperitoneally.
The i.p. doses were given in saline and the
oral doses were suspended in tragacanth
mucilage. Blood was collected by heart
puncture 15 and 30 min after drug adminis-
tration. It was collected in non-heparinized
tubes and allowed to clot, when the serum
was separated by centrifugation and stored
in separate tubes at 4°C until it could be
measured.
(b) Human serum concentrations of metro-
nidazole.-Seven patients in hospital for
palliative radiotherapy to advanced malig-
nancies were told about the object of this
work and their permission obtained. Radio-
therapywas commenced before any metroni-
dazole was administered so that the degree
of any nausea produced by the radiotherapy
alone could be assessed. Thus, the assess-
ment of any enhanced effect on the tumour
tissue was precluded in this study.
As the upper small intestine is believed
to be the site of maximal absorption of
metronidazole, doses of 4-15 g were given
2 or 3 h after breakfast (it was felt unreason-
able at the present stage to fast the patients
to promote more rapid absorption). The
drug was given as a single draught (crushed
400 mg tablets in 30 ml of liquid extract of
liquorice B.P.C.) just after a venous blood
specimen was taken for control purposes.
Further venous blood specimens were taken
at appropriate intervals and prepared for
measurement as described above. Liver
function tests (aspartate transaminase and
alkaline phosphatase activities) and full
blood counts were performed before treat-
ment and regularly thereafter.
Metronidazole concentration determina-
tions in the serum specimens were made
using a polarographic technique (Kane, 1961)
without further preparation, except for the
removal of oxygen from the specimen by
bubbling with pure nitrogen just before
measurement.
Radiotherapy was continued, the radia-
tion being given approximately 2 h after the
drug was administered.
RESULTS
Muiarine serum concentration of metroni-
dazole
Thirtyminutesafterdosagesof25-1000
mg/kg body weight given i.p. in 1-3 ml
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FIG. 1.-Serum concentrations of metronidazole in mice. Note log dose scale for comparison with
Fig. 2. * 30 min after intraperitoneal injection of (lrug in normal saline, @ 30 min after oral
dosing of the drug suspendedl in tragacanth mucilage.
metroni(lazole are linearly related to the
dose administered (Fig. 1). The full line
is a linear relationship and is normalized
to the 25-mg/kg point; the metronidazole
concentration has been plotted on a
logarithmic scale for convenience. Also
shown in Fig. 1 are the values for higher
drug doses given orally in suspension.
Human serunm concentrations of metroni-
dazole
Details of the metronidazole doses
given to 7 patients, together with the
peak serum concentrations achieved, are
given in the Table. A linear relationship
between the peak serum concentration
and the drug dose expressed in mg per kg
body weight was found (Fig. 2). The
time after administration of the drug
required to reach the peak concentration
in the serum is listed in the Table. When
the drug was given only 2 h after break-
fast, the time taken to reach the peak
concentration was at least 2 h; but when
given 3 h after food it was between one
and 2 h.
The time/serum concentration curves
for the several patients are all of the
same general form as shown for one
patient (Fig. 3). Two features are worthy
of notice. The drug concentration re-
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FIG. 2. Peak concentrations of metronida-
zole in human serum. 0 Given 2 h after
breakfast, A given 3 h after breakfast,
* given 3 h after breakfast to obese
patients.
mains at or near the peak value for
a considerable length of time so that
diffusion to the anoxic cell foci furthest
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TABLE.-Human Serum Concentrations of letronidazole, Synopsis of Data
Subject Weight
No. (kg)
Mletronidazolc
dose
(mg/kg)
1 50 1080
Time peak
measured
(h)
2
1
32 3
27- 7
2
2
2
1 .5
1
2
2
2
2
Given 2 h after
breakfast
Given 3 h after
breakfast
TIME (h)
FIG. 3.-Time serum concentration curve of metronidazole for a patient given 2 doses
of metronidazole 48 h apart.
from blood vessels would be facilitated.
The serum level remains high long enough
for radiotherapy at conventional dose
rates to be given conveniently during the
following hours. After an initial half-life
of the drug in the serum of between 6
and 12 h, there is a long tail to the curve.
Peak serum concentrations in excess of
200 ,tg/ml were always obtained after
dosages of metronidazole of 180 mg/kg
body weight or more. These results are
consistent with those for lower doses of
metronidazole recently reported by Urta-
sun et al. (1974).
Doses of metronidazole up to 180
mg/kg were well tolerated, the patients
complaining only of slight but acceptable
nausea. Higher dosages of up to 300
mg/kg were progressively less well toler-
ated, due to severe nausea which persisted
for 24-48 h after the drug had been given.
When these higher doses were repeated
after 48 h, the nausea was unacceptable
and difficult to control with the regular
use of antiemetics (perphenazine (Fen-
tazin) 4 mg given 4-6 hourly). Patients
also complained of the bitter taste of
the drug due to secretion into the mouth
in the saliva which persisted until it
had been largely eliminated from the
body. The results of the liver function
tests and whole blood counts showed no
significant changes during treatment and
for up to 3 weeks thereafter.
DISCUSSION
The measured serum concentrations
of metronidazole in mice used in the
2
3
3
40
40
57 7
57.7
62
62
62
51 -2
74
83
83
83
Peak serum
cone.
(Ug/ml)
102
187
300
124
173
165
202
205
280
340
245
205
240
195
4
5
150
220
130
170
160
190
240
230
160
120
120
120
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" tumour control " andt " cell loss " ex-
periments are high (400-500 /ig/ml) and
have not been reached in patients.
Furthermore, our studies show that they
would not be tolerated in patients,
except perhaps as single doses, and
therefore could not be used with fraction-
ated radiotherapy.
WNThen a comparison is made of the
sensitizing effect of metronidazole at
similar concentrations for in vivo aind in
vitro test systems, a loss of sensitiziing
efficiency in vivo is noted. This is true
both for normal skin rendered artificially
hypoxic (Denekamp et al., 1974) or for
solid tutnours containing hypoxic cells
(Begg et at., 1974; Ratuth and Kaufnman,
1.974), as compared with Chinese hamster
cells in vitro (Asquith et al., 1974). It
has been shown that alterations of cell
growth conditions (McNally, 1 974, per-
sonal coimmunication) and the chemical
environmnent of cells (Asquith et al., 1 974)
affect the sensitizing effect produced by
a given concentration of metronidazole.
The possibility that a significant diffusion
gradient exists between the anoxic cells
and the serum needs to be considered.
However, the physical and chemical pro-
perties of the clrug and the fact that
normal tissues show the same effect as
tumours irradiated in air, make this
unlikely. In our opinion, therefore, these
facts prohibit the use of in vitro data
alone to predict the dosage of a sensitizing
drug needed to produce a similar radio-
sensitizing effect in man (a fuller dis-
cussion of this important point is given by
Asquith et at., 1974).
In spite of this loss of sensitizing
efficiency in vivo, significant enhancement
of radiation damage to solid tumouLrs
(Regg et al., 1974; Rauth and Kaufman,
1974) has been obtained using drug (loses
giving peak serum concentrations of about
200 /ig/ml. It was therefore considered
worthwhile to see if this drtug conceintra-
tion in the seruml couild be reached in
hIuman patients. In fact, peak serumn
concentrations of metronidazole greater
than 20() ig/ml were reliably obtaiined
with dosages above 180 mg/kg and in
4 instances with smaller dosages.
The properties of metronidazole and
its pharmacology (for references see
Asquith et al., 1974) indicate that the
drug equilibrates rapidly throughout the
body and no evidence showing the drug
to concentrate in any one tissue has
been reported for either mice or man.
Assuming this to be the case, then
calculations suggest that even higher
serum levels in man were expected (by
about 20%) than were actually measured.
This could be explained by assuming that
the rate of absorption of metronidazole
from the gastrointestinial tract is limited
so that a significant amount is excreted
before complete absorption can occur.
As no toxic symptoms other than transient
nausea have been experienced by any
of the patients with serum levels of up
to 340 ,ig/ml, then if more rapid absorp-
tion of metronidazole cani be promoted,
higher serum concentrations may be
obtained without increasing the dose
administered.
The time-concentration curve (Fig. 3)
indicates that there is plenty of time
for radiation treatment to be given
before the serum concentrationi falls appre-
ciably. A further point to note is the
long time required for complete elimina-
tion of the drug from the serum. Faster
elimination may be helpful in reducing
the duration of nauseous symptoms. As
the drug is excreted in the urine largely
unchanged, then adequate renal function
and fluid intake are desirable.
The lack of toxicity, apart from
nausea, associated with even the highest
drug (lose employed is encouraging and
agrees with the murine tumour experi-
ments where no increased morbidity was
associated with the increased cure rate
(Begg et at., 1]974). One patient received
a total of 55 g of metronidazole in less
than 3 wNveeks (Table) and showed neither
abnormal liver functioii test results nor
blood couniits up to 3 weeks later. Doses
of metronicdazole giving serum levels of
200 /ig/ml were on the borderline of
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acceptability to patients due to the
nausea produced. Tolerance to doses of
metronidazole of this order would be
dependent on controlling nausea and
would, in our experience, not be repeat-
able more than twice or perhaps 3 times
a week.
It is concluded that peak serum
concentrations of 200 ,ug/ml in patients
could be reliably obtained with single
doses of metronidazole of 180 mg/kg
body weight. This is a smaller dose
than that predicted from the studies in
mice (Fig. 1). Whether the enhancement
ratio of 1 2 obtained for the single dose
radiation treatment of the KHT sarcoma
(Rauth and Kaufman, 1974) and the C3H
mammary carcinoma (Stone and Withers,
1974) would be detectable clinically using
fractionated radiotherapy would depend
on how steep is the dose response curve
for local tumour control. This parameter
has been shown to be dependent upon
the anatomical site and clinical variety
of the cancer (Fletcher, 1973). From
the data of Schukovsky (1970) and Bush
(1974) increases of 10-70% and 50-70O
respectively would be predicted, and a
formal clinical trial would be required to
detect such increases.
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